BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20170766)

  • 1. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7.
    Adachi K; Kawana K; Yokoyama T; Fujii T; Tomio A; Miura S; Tomio K; Kojima S; Oda K; Sewaki T; Yasugi T; Kozuma S; Taketani Y
    Vaccine; 2010 Apr; 28(16):2810-7. PubMed ID: 20170766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner.
    Taguchi A; Kawana K; Yokoyama T; Adachi K; Yamashita A; Tomio K; Kojima S; Oda K; Fujii T; Kozuma S
    Vaccine; 2012 Aug; 30(36):5368-72. PubMed ID: 22727726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
    Komatsu A; Igimi S; Kawana K
    Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Administration of Poly-Gamma-Glutamic Acid Significantly Enhances the Antitumor Effect of HPV16 E7-Expressing
    Kim E; Yang J; Sung MH; Poo H
    J Microbiol Biotechnol; 2019 Sep; 29(9):1444-1452. PubMed ID: 31387341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral administration of human papillomavirus type 16 E7 displayed on Lactobacillus casei induces E7-specific antitumor effects in C57/BL6 mice.
    Poo H; Pyo HM; Lee TY; Yoon SW; Lee JS; Kim CJ; Sung MH; Lee SH
    Int J Cancer; 2006 Oct; 119(7):1702-9. PubMed ID: 16646080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.
    Kawana K; Adachi K; Kojima S; Taguchi A; Tomio K; Yamashita A; Nishida H; Nagasaka K; Arimoto T; Yokoyama T; Wada-Hiraike O; Oda K; Sewaki T; Osuga Y; Fujii T
    Vaccine; 2014 Oct; 32(47):6233-9. PubMed ID: 25258102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization with recombinant Lactococcus lactis NZ9000 expressing human papillomavirus type 16 E7 antigen and evaluation of its immune effects in female C57BL/6 mice.
    Mohseni AH; Razavilar V; Keyvani H; Razavi MR; Khavari-Nejad RA
    J Med Virol; 2019 Feb; 91(2):296-307. PubMed ID: 30192395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing Lactobacillus casei in C57BL/6 mice.
    Lee TY; Kim YH; Lee KS; Kim JK; Lee IH; Yang JM; Sung MH; Park JS; Poo H
    Cancer Immunol Immunother; 2010 Nov; 59(11):1727-37. PubMed ID: 20706715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
    Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
    Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.
    Manuri PR; Nehete B; Nehete PN; Reisenauer R; Wardell S; Courtney AN; Gambhira R; Lomada D; Chopra AK; Sastry KJ
    Vaccine; 2007 Apr; 25(17):3302-10. PubMed ID: 17291642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer.
    Ajorloo M; Alamdary A; Soleimanjahi H; El Boulani A; Khanizadeh S; Nikoo HR
    Microb Pathog; 2019 Jul; 132():20-25. PubMed ID: 31004722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
    Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
    Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
    Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
    Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
    J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL; Qiu XH; Shen C; Liu JN; Zhang J
    Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.